- Long-term venture capital investors holding reduced to 28% of share capital
- Private investors acquired shares from venture capitalist investors in secondary block trades
Zurich-Schlieren, April 6, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today reported changes in ownership based on disclosure notifications received according to Article 120 of the Swiss Financial Market Infrastructure Act. According to such disclosure notifications, three investors crossed the following thresholds on April 5, 2017: Index Ventures Funds fell below 10% to 8.18%; Essex Woodlands Health Ventures Funds, below 10% to 7.82%, and Johnson & Johnson Innovation, below 5% to 4.25%. Private investors acquired shares from venture capitalist investors in secondary block trades.
“We are pleased to report the continued evolution of our shareholder base as we advance innovative DARPin® therapies to benefit patients. We are grateful for the continued support of long-term investors who recognized the clinical and commercial potential of our DARPin® platform more than a decade ago,” said Patrick Amstutz, acting Chief Executive Officer of Molecular Partners. “The natural rotation of our shareholder base enables the continued progress of Molecular Partners as we approach multiple value inflection points in 2018 and beyond, including the anticipated one-year readout of the efficacy data from two Phase 3 clinical trials of abicipar, our lead compound for wet age-related macular degeneration being developed in partnership with Allergan and the initial readout of our proprietary MP0250 study in multiple myeloma and an additional solid tumor indication.”
|April 13, 2017||Expected Publication of Invitation the Annual General Meeting 2017|
|May 4, 2017||Q1 2017 Management Statement|
|May 11, 2017||Annual General Meeting|
|August 30, 2017||Publication of 2017 Half-year Results|
|October 26, 2017||Q3 2017 Management Statement|
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details please contact:
Dr. Patrick Amstutz, acting CEO
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 43 344 42 42
Susan A. Noonan Communications, LLC
Tel: +1 212 966 3650
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.